Physician

Aminder S Mehdi, MD

According to 2025 Medicare claims, Aminder Mehdi, MD (NPI: 1780612507) practices hematology/oncology in the Stockton-Lodi, CA market, with the plurality of this provider's patient population coming from San Joaquin, CA. This provider's primary affiliated billing organization is STOCKTON HEMATOLOGY ONCOLOGY MEDICAL GROUP, INC (NPI: 1922175074; TIN: 20-3850829) and primary practice location at 95204-5500.

Mehdi's data goes back to 2015 and runs through 2024. For example, in 2024, this provider had 669 traditional Medicare patients, billed 272,740 HCPCS/CPT codes, and received $5,726,267 in Medicare payments. The top billing code was 99205 (New patient office or other outpatient visit with a high level of medical decision making, if using time, 60 minutes or more). Part D data shows 2,009 prescription claims across 369 beneficiaries totaling $6,039,141 in drug costs, led by Xtandi (Enzalutamide). DME data shows 58 claims. Open Payments data shows 56 records totaling $1,495. You can download detailed data with all billing codes (2015-2024). For more recent data, please contact us.

Over the past 10 years, this provider's Medicare Part B carrier billing has risen steadily, from $1,940,048 to $5,726,267. Similarly, Part D prescription costs have moved sharply higher in recent years, from $2,116,306 to $6,039,141. In contrast, DME billing represents a smaller volume and moved sharply higher in recent years, from $3,471 to $23,304.

Part B Carrier Billing Trend

Medicare payment trend, with N of patients and claim lines in the table.

Year	Patients	Clm Lines	Payment
2015	544	132,565	$1,940,048
2016	592	161,387	$2,635,674
2017	558	198,346	$3,201,895
2018	577	207,186	$3,486,143
2019	573	243,239	$3,764,915
2020	561	218,160	$3,711,821
2021	556	215,675	$3,977,732
2022	614	213,049	$4,229,736
2023	665	231,021	$4,177,913
2024	669	272,740	$5,726,267

Part D Events Trend

Drug cost trend, with N of patients and prescription claims in the table.

Year	Patients	Claims	Drug Cost
2015	246	1,691	$2,116,306
2016	273	1,591	$2,350,081
2017	275	1,636	$2,707,838
2018	258	1,607	$2,711,417
2019	294	1,713	$2,434,634
2020	259	1,693	$2,831,161
2021	293	1,769	$4,570,128
2022	289	1,740	$4,779,590
2023	343	1,951	$5,405,354
2024	369	2,009	$6,039,141

DME Billing Trend

Medicare payment trend, with N of patients and DME claim records in the table.

Year	Patients	Claims	Payment
2015	N/R	92	$39,227
2016	12	81	$22,008
2017	12	41	$11,917
2018	39	138	$15,354
2019	N/R	68	$6,352
2020	N/R	92	$6,087
2021	N/R	83	$4,886
2022	N/R	N/R	N/R
2023	N/R	77	$15,230
2024	11	58	$1,476

* / # = suppressed by CMS; 0 = reported zero; N/R = not reported or blank.

Top 5 Part B carrier billing codes in 2024

By total payments.

Code	Description	Patients	Clm Lines	Total Payment
99205	New patient office or other outpatient visit with a high level of medical decision making, if using time, 60 minutes or more	116	116	$163
99215	Established patient office or other outpatient visit with high level of medical decision making, if using time, 40 minutes or more	203	369	$141
99214	Established patient office or other outpatient visit with moderate level of decision making, if using time, 30 minutes or more	402	885	$95
99213	Established patient office or other outpatient visit with low level od decision making, if using time, 20 minutes or more	168	236	$69
96372	Injection of drug or substance under skin or into muscle	123	523	$11

Top 5 Part D drugs in 2024

By total drug costs.

Drug	Generic	Claims	Total Day Supply	Total Drug Cost
Xtandi	Enzalutamide	94	2,820	$1,267,544
Revlimid	Lenalidomide	30	840	$617,951
Pomalyst	Pomalidomide	30	819	$610,321
Tasigna	Nilotinib Hcl	26	728	$531,270
Erleada	Apalutamide	26	780	$367,249

Top 5 DME services in 2024

By Total Medicare Payment Amount.

HCPCS Code	HCPCS Description	Supplier Rental Indicator	Total Supplier Beneficiaries	Total Supplier Claims	Total Medicare Payment Amount
J8521	Capecitabine, oral, 500 mg	N	N/R	21	$540
J8530	Cyclophosphamide; oral, 25 mg	N	N/R	12	$522
Q0511	Pharmacy supply fee for oral anti-cancer, oral anti-emetic or immunosuppressive drug(s); for the first prescription in a 30-day period	N	11	25	$414

Open Payments Summary in 2024

Category	Definition	Records	Total Reported Amount	Top Related Entity
General Payments	Reported payment or transfer-of-value amount.	56	$1,495	Novartis Pharmaceuticals Corporation
Research Payments	Reported research-related payment or transfer-of-value amount.	0	$0	N/R
Ownership / Investment Interests	Reported value of ownership or investment interests.	0	$0	N/R

Explore More Providers

FAQ

What Medicare data is available for Aminder S. Mehdi, MD?

Tedicare shows public-source Medicare data for Aminder S. Mehdi, MD (NPI 1780612507), including provider identity, specialty, market context, Medicare Part B activity, Part D prescribing, DME records, Open Payments where available, billing organization details, and ACO affiliation signals where available. Profile data covers 2015-2024, with current attribution based on 2025 claims where available.

Does Aminder S. Mehdi, MD have ACO affiliation data?

No ACO affiliation record is shown in the available Tedicare data for this profile.

What billing organization is linked to Aminder S. Mehdi, MD?

Aminder S. Mehdi, MD is linked to STOCKTON HEMATOLOGY ONCOLOGY MEDICAL GROUP, INC (billing NPI 1922175074) in the available physician profile data.

Does Aminder S. Mehdi, MD have Open Payments data?

Aminder S. Mehdi, MD has 56 connected Open Payments records in the available 2024 summary data.

Can I download physician-level Medicare data from Tedicare?

Yes. Tedicare provides sample physician export data and paid custom physician data exports for research, planning, outreach, and market analysis. Exports can include physician profile fields, market and specialty context, billing organization details, ACO affiliation signals where available, and Medicare utilization data.